Y Intercept Hong Kong Ltd Trims Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Y Intercept Hong Kong Ltd lessened its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 89.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,251 shares of the company's stock after selling 42,876 shares during the period. Y Intercept Hong Kong Ltd's holdings in Protagonist Therapeutics were worth $236,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. New York State Teachers Retirement System acquired a new stake in Protagonist Therapeutics during the 3rd quarter worth approximately $1,107,000. Seven Eight Capital LP lifted its holdings in shares of Protagonist Therapeutics by 426.9% during the second quarter. Seven Eight Capital LP now owns 36,793 shares of the company's stock worth $1,275,000 after purchasing an additional 29,810 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Protagonist Therapeutics by 9.1% during the second quarter. Bank of New York Mellon Corp now owns 204,299 shares of the company's stock worth $7,079,000 after purchasing an additional 17,065 shares during the period. Swedbank AB bought a new stake in shares of Protagonist Therapeutics in the third quarter worth $2,250,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Protagonist Therapeutics by 7.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 565,503 shares of the company's stock valued at $25,448,000 after purchasing an additional 39,850 shares during the period. Institutional investors own 98.63% of the company's stock.

Insider Buying and Selling at Protagonist Therapeutics

In related news, insider Suneel Gupta sold 103,437 shares of the business's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $46.04, for a total transaction of $4,762,239.48. Following the transaction, the insider now directly owns 256,174 shares in the company, valued at approximately $11,794,250.96. The trade was a 28.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Arturo Md Molina sold 26,000 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $44.70, for a total value of $1,162,200.00. Following the completion of the transaction, the insider now owns 46,444 shares in the company, valued at $2,076,046.80. The trade was a 35.89 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 209,863 shares of company stock valued at $9,689,847. Corporate insiders own 5.40% of the company's stock.

Analyst Ratings Changes

PTGX has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Protagonist Therapeutics in a report on Tuesday, December 10th. Truist Financial began coverage on shares of Protagonist Therapeutics in a research report on Monday, September 9th. They set a "buy" rating and a $60.00 target price for the company. BMO Capital Markets initiated coverage on shares of Protagonist Therapeutics in a research note on Friday, December 6th. They issued an "outperform" rating and a $62.00 price objective on the stock. TD Cowen raised shares of Protagonist Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 25th. Finally, Wedbush reaffirmed an "outperform" rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $53.78.

Protagonist Therapeutics Trading Up 1.3 %

NASDAQ PTGX traded up $0.52 during mid-day trading on Thursday, hitting $39.54. The company's stock had a trading volume of 747,094 shares, compared to its average volume of 741,659. The firm has a market capitalization of $2.36 billion, a price-to-earnings ratio of 14.86 and a beta of 2.18. The company's 50 day simple moving average is $44.09 and its 200 day simple moving average is $40.80. Protagonist Therapeutics, Inc. has a twelve month low of $20.71 and a twelve month high of $48.89.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.